Targeting a specific protein in certain lung cancers
Official title: Targeting SMARCA2 in SMARCA4-deficient lung cancers in vivo
Funded at Columbia University Health Sciences · NIH-11108373 · Data updated 2026-11-12
This study is looking at how a protein called SMARCA2 affects lung cancers that don't have another important protein, SMARCA4, and it aims to find new treatments by figuring out if reducing SMARCA2 can help slow down tumor growth for patients with this specific type of lung cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 17, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $557,418 |
| NIH project number | 1R37CA300526-01 |
| Project ID | NIH-11108373 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, specifically those with SMARCA4 alterations.
✕Less likely to help
Patients with lung cancers that do not have SMARCA4 deficiencies or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates the role of SMARCA2 in lung cancers that lack the SMARCA4 protein, which is crucial for tumor suppression. By using genetically engineered mouse models, the study aims to understand how degrading SMARCA2 can affect tumor growth and progression in these cancers. The approach involves developing targeted therapies that could selectively inhibit SMARCA2, potentially leading to new treatment options for patients with this specific type of lung cancer. The research seeks to fill a significant gap in effective therapies for patients with SMARCA4-deficient lung adenocarcinomas.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and treatment responses for patients with SMARCA4-deficient lung cancers.
How similar studies have gone: While targeting SMARCA2 in this context is a novel approach, previous studies have shown promise in targeting similar pathways in cancer treatment.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Concepcion-Crisol, Carla P — Columbia University Health Sciences
- Study coordinator: Concepcion-Crisol, Carla P
Related research
Other NIH-funded projects on the same topics.
-
TRIM28 Inhibition for NOTCH2-Mutant Small Cell Lung Cancer
A new approach aims to exploit a weakness in a subset of small cell lung cancer by turning on immune-related signals when NOTCH2 is lost, potentially making tumors more visible to the immune system.
-
Genomic factors shaping lung cancer risk in Native Hawaiians and Pacific Islanders
This NIH grant focuses on understanding why Native Hawaiians, Pacific Islanders, and African Americans have higher lung cancer risk and poorer outcomes by studying tumor DNA and related molecular patterns.
-
PD-L1 PET tracer to guide immune therapy in non-small cell lung cancer
A Johns Hopkins team is testing a Gallium-68 PET tracer to better guide immune checkpoint therapy for people with non-small cell lung cancer.
-
Targeting SMARCA2 to treat lung cancers that lack SMARCA4
This work looks at whether blocking a protein called SMARCA2 can slow or stop lung cancers that have lost the related gene SMARCA4.
-
New medicines for lung cancers caused by KRAS or BRAF changes
Testing new medicines that block ERK/RAF signaling in people with lung cancer driven by KRAS or BRAF mutations.
-
Understanding lung cancer risks in Native Hawaiians
This research looks at the genetic differences in lung cancer among Native Hawaiians to better understand why they face higher risks and poorer outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.